Of note, a selective small molecule inhibitor targeting the HIF-2α transcription factor, Belzutifan (MK-6482), has been reported to reduce the size of tumours and inhibited tumour progression in almost 90% of von Hippel–Lindau (VHL) patients over a 3-year study period [10,11]. This evidence concerns the gene VHL and neoplasm.